HONG KONG, Nov. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), winning Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact.
HERA celebrates excellence in sustainability reporting and ESG practices, with award categories spanning ESG governance, environmental and social impact, carbon neutrality, and workplace well-being. The program is independently judged by a panel drawn from academia, finance, sustainability advisory and regulatory backgrounds, promoting transparency, accountability and stakeholder trust.
Selected from 120 entries, WuXi Biologics was the only pharmaceutical company to receive a Grand Award this year. Its two honors recognize WuXi Biologics' continual efforts to advance transparent, high-quality ESG disclosure and deliver measurable environmental progress across its global operations.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are delighted to receive two HERA awards, which reflect our ongoing conviction that transparent ESG disclosure and strong environmental performance are integral to business resilience and long-term success. WuXi Biologics will continue to advance our ESG governance and Green CRDMO strategy, working with global partners to drive sustainable development across the value chain."
Through its Green CRDMO solutions, the Company continues to embed sustainability principles throughout its biologics research, development, manufacturing, and operations. In 2025, WuXi Biologics' near-term, long-term and net-zero greenhouse gas emissions reduction targets were validated by the Science Based Targets initiative (SBTi), covering Scope 1, 2 and 3 emissions and aligned with a 1.5°C pathway. Another honor WuXi Biologics recently received was being named to the 2026 Forbes China ESG 50 list for achievements in sustainable development, Green CRDMO solutions, and ESG digital innovation.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.
With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)
*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence
LONDON, Nov. 12, 2026 /PRNewswire/ -- FCM Travel, the flagship corporate travel arm of Flight Centre Travel Group (FCTG), has appointed Mark McSpadden as Chief Product Officer (CPO) as it steps up its investment in product, innovation and proprietary technology. McSpadden will own FCM's end-to-end product and AI strategy, including the development and future integration of its core capabilities.
The appointment is part of FCM's wider expansion of its proprietary technology and investment in experienced leaders to better serve multinational customers. McSpadden will oversee product development and lead the partnerships and integrations that connect with FCM's technology.
McSpadden will work alongside Melissa Elf, FCM's Global Managing Director, as part of the FCM leadership team, together with Jessica Dunderdale, FCM's Global Head of Product, who will continue to lead the work connecting product strategy with customer needs and ensuring the technology creates value. He will also join the FCTG technology management team and report to John Morhous, Chief Experience Officer across FCTG's corporate brands.
"Our customers want technology that makes travel simpler for people and easier to manage for their travel teams," said Elf. "Mark brings deep product expertise from across travel and broader technology sectors, and he will help us move faster on the capabilities we build ourselves. Our technology and our people work as one, and Mark's focus on the experience of the travellers and travel managers using it will make that connection even stronger."
Morhous added: "Corporate travel technology is more crowded than it has ever been, and our customers need a partner who can cut through that and build what actually works. Mark has led product at global scale across travel and beyond, and he brings the experience to connect everything we offer and take it further. Working with the wider team, he gives FCM the product leadership to keep raising the bar for our customers."
McSpadden, based in Dallas, Texas, joins with more than 15 years' leadership in travel at the intersection of product, technology and innovation. He was Vice President of Global Product & UX at Amex GBT, guiding a portfolio of more than 20 products across the traveller and travel manager experience. Before that, he held several roles at Sabre including Vice President of Digital Experience for Sabre Hospitality and Vice President of Emerging Products & Technology, where he led Sabre Labs' exploration of the future of travel and technology. His background also spans e-commerce and technology roles in retail and financial services. Most recently, he was Head of Innovation at USAA Labs, a financial services company.
"FCM has a unique opportunity to bring its proprietary technology, human expertise, and the latest developments in AI together into one connected experience for customers," said McSpadden. "I'm particularly excited to work on an elevated use of data to help travel managers and travellers get more value from the tools already available to them. I'm looking forward to leading the future vision of FCM's technology strategy and shaping it with our customers."
About FCM Travel
FCM is one of the world's largest travel management companies and a trusted partner for thousands of national and multi-national organisations, including many household brands, Fortune, and FTSE 100 companies. With a 24/7 reach in 95 countries, FCM's agile and flexible technology anticipates and solves client needs supported by expert teams who provide in-depth local knowledge and duty of care as part of the ultimate personalised business travel experience.
As the flagship corporate travel arm of Flight Centre Travel Group, FCM is able to deliver some of the most competitive rates, unique added-value benefits, and exclusive solutions for its clients to support their business travel requirements. A recognised leader in the travel tech space, the company has debuted several proprietary client solutions over the last 12 months including a new omnichannel platform featuring a "first of its kind" customised end-to-end user experience and FCM Booking, an innovative option to traditional OBTs.
Alongside its travel management services, the company provides specialist services through FCM Consulting and FCM Meetings & Events to service broader needs of clients. Discover the alternative at www.fcmtravel.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
FCM Travel appoints Mark McSpadden as Chief Product Officer to lead product and AI strategy
